Ads
related to: high intensity ultrasound prostate cancer screening- Find an Imaging Site
Locate the nearest imaging site
or contact customer service.
- Case Studies
Review real case studies
with real patients.
- Contact Us
Contact our representatives
for product and reimbursement info.
- Sign Up for Updates
Sign up to receive the latest data,
case studies, and resources.
- Find an Imaging Site
Search results
Results From The WOW.Com Content Network
Prostate cancer is the second most common cause of cancer death among men, according to the American Cancer Society. This year, the organization projects that about 300,000 new cases will be ...
Prostate cancer screening is the screening process used to detect undiagnosed prostate cancer in men without signs or symptoms. [ 1 ] [ 2 ] When abnormal prostate tissue or cancer is found early, it may be easier to treat and cure, but it is unclear if early detection reduces mortality rates.
Studies on localized prostate cancer showed that, after treatment, progression-free survival rates were high for low- and intermediate- risk patients with recurrent prostate cancer. [3] The InsighTec ExAblate 2000 was the first MRgFUS system to obtain FDA market approval, [4] US patent 5,247,935.
Treatment for prostate cancer may involve active surveillance, surgery, radiation therapy – including brachytherapy (prostate brachytherapy) and external-beam radiation therapy, proton therapy, high-intensity focused ultrasound (HIFU), cryosurgery, hormonal therapy, chemotherapy, or some combination. Treatments also extend to survivorship ...
When PSA screening began in the 1980s, cases of prostate cancer rose by 26% between 1986-2005, with the most affected age group being men under the age of 50. [37] Prostate cancer is a heterogeneous disease, and the cancer will grow aggressively in approximately 1 in 3 cases. Therefore there is a risk of overdiagnosing and overtreating, this ...
In a separate study of men from the pre prostate cancer screening era managed with watchful waiting (56% over age 70 years), progression to distant metastasis or prostate cancer death was 13.9% and 12.3%, respectively for Gleason score 6 or below, but considerably higher at 18.2 and 22.7%, 30% and 20%, 44.4% and 55.6% for Gleason 3+4, 4+3, and ...
Ads
related to: high intensity ultrasound prostate cancer screening